- Describe how hereditary cancer genetic testing and tumor genomic profiling influences treatment and management decisions for patients with gastrointestinal cancers.
- Apply strategies for integrating germline and somatic testing into multidisciplinary GI cancer care, addressing barriers to implementation of universal testing recommendations and improving access to timely testing.
Turning Genetic Insights into Action: Advancing Precision Care in Gastrointestinal Cancers
2026 CGA-IGC ANNUAL MEETING BREAKFAST SEMINAR
As recommendations for universal genetic testing continue to expand in gastrointestinal (GI) cancers, multidisciplinary teams face increasing opportunities to incorporate genetic insights into patient care. This seminar will highlight the role of germline genetic testing across the GI cancer continuum, from surgical planning to systemic treatment selection and emerging molecular residual disease approaches.
Through expert perspectives from colorectal surgery and medical oncology, attendees will gain practical insights into how germline and somatic testing can work together to inform precision care. The discussion will address common implementation barriers and explore strategies for improving adoption of universal testing recommendations in clinical practice.
Learning Objectives:
Breakfast and beverages will be provided. This event is exclusively for registered 2026 CGA-IGC Annual Meeting attendees.
*This seminar is supported by Myriad Genetics through a marketing grant. Not CME-accredited.
LIMITED SEATING. RSVP NOW.
SPEAKERS
Asaf Maoz, MD
Dana-Farber Cancer Institute
Dr. Maoz is a Gastrointestinal Medical Oncologist in the Division of Genetics and Prevention and the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, and an instructor at Harvard Medical School. Dr. Maoz's research focuses on the detection and prevention of hereditary cancers and the treatment of cancers of the gastrointestinal tract.
Katherine Prince, MS, CGC
Dana-Farber Cancer Institute
Katherine Prince is a cancer genetic counselor at Dana-Farber Cancer Institute in Boston, Massachusetts, where she provides hereditary cancer risk assessment and counseling for adult oncology patients. She received her Master of Science in Genetic Counseling from Brandeis University in 2022. Her clinical interests include hereditary gastrointestinal cancer syndromes, particularly Lynch syndrome. In addition to her clinical work, Katherine is passionate about genetics education and enjoys presenting to and educating healthcare providers on hereditary cancer. She is also dedicated to genetic counseling education through supervising graduate students, mentoring prospective genetic counselors, and supporting the development of future genetics professionals.
About Myriad Oncology™
Myriad Oncology, a business unit of genetic testing and precision medicine leader Myriad Genetics, provides an expanding portfolio of advanced genetic and tumor genomic testing solutions, meeting the specific needs of clinicians and their oncology patients. Myriad Oncology products support each step in the cancer care continuum, empowering clinicians and their patients with confidence and clarity to navigate the unique challenges of each cancer journey. For more information, visit https://myriad.com/oncology/.
We Are Live In
Location
Myriad Genetics, Inc. / 322 North 2200 West, Salt Lake City, UT 84116 ©2026 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.